Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures

PHASE4

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped After reevaluation of the benefit: risk profile of ezogabine/retigabine, GSK does not believe the early adjunctive treatment study population is appropriate.

Conditions

Seizures

Interventions

DRUG: Ezogabine/Retigabine IR
DRUG: Placebo

Sponsor

GlaxoSmithKline

Collaborators

[object Object]